1Faulds D, Heel RC. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections[ J ]. Drugs, 1990,39 (4) : 597 - 638.
2Nevins TE, Dunn DL. Use of ganciclovir for cytomegalovirus infection[J ]. J Am Soc Nephrol, 1992,2( 12 suppl) : s270 - s273.
3Elion GB, Furman PA, Fyfe JA, et al. The selectivity of action of an antiherpetic agent, 9- ( 2-hydroxyethoxymethyl ) guanine [ J ]. Rev Med Virol, 1999,9(3) : 147 - 152.
4Steer CB, Szer J, Sasadeusz J, et al. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir[J ]. Bone Marrow Transplant, 2000,25 (6) : 657 - 664.
5McGavin JK,Goa KL. Ganciclovir:an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients[J]. Drugs, 2001,61(8) : 1153-1183.
6Velez G, Roy CE, Whiptcup SM, et al. High-dose intravitreal ganciclovir and foscarnet for cyto-megalovirus retinits[J]. Am J Ophthalmol,2001,131(3) :396 - 397
7Frenkel LM, Capparelli EV, Dankner WM, et al. Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects, the pediatric AIDS chinical trial group [J ]. J Infect Dis, 2000, 182 ( 6 ):1016 - 1024
8Mouly S, Aymard G, Diquet B, et al. Oral ganciclovir systemic exposure is enhanced in HIV-infected patients with diarrhea and weight loss[J].J Acquir Immune Defic Syndr,2000,24(4) :344 - 351
9Dubrenil-Lemaire ML,Gori A, Vittecoq D, et al. Lenograstim for the treatment of neutropenia in patients receiving ganciclovir for Cytomegalovirus infection:a randomised, placebo-controlled trial in AIDS patients[J ]. Eur J Haematol, 2000,65 (5): 337 - 343
